First Case of Severe Pain and Inflammation Reduction by Application of Purified Amniotic Fluid on Active Lesions of a Patient with Pyoderma Gangrenosum

Ann Case Rep. 2023;8(6):1566. doi: 10.29011/2574-7754.101566. Epub 2023 Dec 26.

Abstract

We report the first case of severe pain and inflammation reduction by application of purified amniotic fluid on active lesions of a patient with pyoderma gangrenosum. We describe the impact of every third-day skin applications of a sterile fraction (4ml) from human purified amniotic fluid (ViX001) obtained from thoroughly screened volunteers at the time of planned c-section at the term of normal pregnancies. The product ViX001 was generated through a proprietary process and kept in frozen one or two milliliters cryovials (protein content was ~1mg/ml) and thawed just prior to applications. Pain improvement was recorded after each application, and inflammation suppression was confirmed by serial pictures of the lesions. While our findings need to be reproduced with a larger cohort of patients, preferably at an earlier stage of the disease, it is instructive that ViX001 reduced severe pain and inflammation for a patient with advanced pyoderma gangrenosum. Pyoderma gangrenosum is a dreadful skin condition consisting of noninfectious neutrophilic dermatosis that progresses to necrotic ulcers with a characteristic purple edge and extremely painful raw subdermal tissue exposure.

Keywords: Exosomes; Extracellular Vesicles; Healing; Immunity; Inflammation; Perinatal Products; Purified Amniotic Fluid; Pyoderma Gangrenosum; Regenerative Medicine; Tissue Repair.